Explore 3 Stock Ideas & Industry Insights Download Free Report

mid-cap

Update on One NASDAQ- Listed Technology Stock Amid Market Uncertainty: TEM

May 05, 2025 | Team Kalkine
Update on One NASDAQ- Listed Technology Stock Amid Market Uncertainty: TEM
Image source: shutterstock

  • TEM:NASDAQ
  • Investment Type
    Mid - Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Tempus AI, Inc

Tempus AI, Inc. (NASDAQ: TEM) is a technology-driven company focused on advancing diagnostics across various disease areas. It combines data and analytics to support personalized medicine. The company operates through three main product lines: genomics, data, and artificial intelligence (AI) applications. Its genomics segment utilizes advanced laboratory technologies to offer next-generation sequencing, diagnostic testing, PCR, molecular profiling, genotyping, and other forms of anatomic and molecular pathology analysis.

As per our previous US Dailies Report published on ‘TEM’ on March 24, 2025, Kalkine provided an Buystance on the stock at USD 51.35 based on fundamental analysis and the stock price has now moved down by ~11.12% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Daily Chart

Considering a volatile market condition led by recent tariffs escalation from United States and subsequent retaliation, recession fear, higher interest rate and geopolitical disruption a ‘Sell’ rating is assigned to the ‘TEM’ at the closing market price of USD 57.06 as of May 02,2025. 

Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 02,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.


Disclaimer-

This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites.  All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.

Past performance is not a reliable indicator of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions